This article reviews 2022–2026 evidence on whether low‑dose (microdosed) CBD might support night‑shift sleep for NHS staff. It covers trial applicability, variable timing (Tmax), drug interactions (notably with clobazam, some antidepressants and opioids), driving safety and the workplace drug‑testing gap, and gives practical steps for staff considering CBD.

Recent RCTs (2019–2026) show limited evidence that CBD improves outcomes when added to CBT or exposure therapy for anxiety. While single‑dose lab studies sometimes show acute anxiolytic effects, long‑term, disorder‑level trials are lacking—UK therapists should adopt a cautious, evidence‑informed approach and document shared decisions with patients.

Now that Veoza is available on the NHS for women who cannot take HRT, interest in non‑hormonal options — including low‑dose CBD and hemp‑derived cannabinoids — is rising. This article summarises the current evidence, practical microdosing approaches, safety considerations and how to discuss options with your GP.